|
The European Community Advisory Board
ECAB was created in 1997. At the time, patient advisory boards only existed on an ad-hoc basis and were convened by the pharmaceutical companies, a major limitation that ECAB successfully overcame by putting forward an innovative model for the patient Community to provide meaningful, independent, and valued input in HIV treatment and prevention research.
EATG, within the remit of the European Community Advisory Board (ECAB), addresses critical scientific questions around HIV drug-development and related co-infections as well as access to treatment in the European region as defined by the World Health Organisation.
ECAB is a high-level scientific platform that brings together civil society, scientific researchers, the pharmaceutical industry and international institutions to address key science and policy issues related to HIV and its main co-infections like hepatitis C or tuberculosis.
ECAB is composed by expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS, broadening access to treatment, training/mentoring new HIV/AIDS advocates and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena. It is a volunteer, Community-based structure, also collaborating actively with national and regional Community Advisory Boards in Europe and other groups sharing the same philosophy in other
ECAB aims to promote the harmonisation of the best available clinical practices, standards of care and access to the latest and best available therapies and diagnostic tools throughout Europe, with a particular regard to Central and Eastern Europe. ECAB members meet regularly with the pharmaceutical industry and researchers to discuss, under confidentiality, the advances in HIV drug development and related co-infections, and access to treatment in the European region. ECAB ‘s work includes:
Members of the ECAB meet in Brussels on a regular basis (see ECAB calendar of meetings)
ECAB meetings don't only focus on HIV/AIDS. Thematic ECAB meetings are also organised on important topics such as hepatitis C or tuberculosis as co-infections. ECAB Steering CommitteeCo-chairs : Paul Clift / Chris Cziria Scientific Officer : Giorgio Barbareschi Steering Committee Members : Giulio Corbelli Evgenia Maron Milena Stevanovic Memory Sachikonye Deniz Uyanik Brian West (BoD Liaison) |
|
||
|
The ECAB co-chairs
ECAB has two co-chairs: members that were elected during the 2012 General Assembly. Paul Clift, UK Chris Cziria, Hungary |
|
||
|
How ECAB works
CAB holds meetings at least 6 times per year for 3 days each. The meeting agenda includes discussions with industry and scientists, lectures by researchers and training sessions.
ECAB members commit to work as group members and on specific tasks they might be assigned to (i. e. company liaison, thematic portfolios, minute taking etc.).
ECAB asks pharmaceutical companies to disclose information of scientific and commercial value as it is available and prior to publication. ECAB receives such information under confidentiality.
|
|
||
